Real world study on the efficacy and tolerability of ixabepilone monotherapy vs. combination therapy with capecitabine in metastatic breast cancer patients (MBC)

被引：0
|
作者：
Hyder, Tara [1 ]
Rosenzweig, Margaret [1 ]
Brufsky, Adam M. [1 ]
机构：
[1] Magee Womens Hosp, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS13-47
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of the combination of docetaxel, capecitabine and carboplatinum as first line therapy in metastatic breast cancer (MBC)
    Mokaddem, Walid
    Kattan, Joseph
    Chahine, Georges
    Nasr, Fadi
    Farhat, Fadi
    Tueni, Elias
    Dagher, Joya
    Younes, Fariha
    Ghosen, Marwan
    ANNALS OF ONCOLOGY, 2004, 15 : 45 - 46
  • [22] Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine.
    Thomas, E.
    Perez, E. A.
    Mukhopadhyay, P.
    Lerzo, G.
    Pivot, X.
    Bosserman, L. D.
    Mullaney, B.
    Vahdat, L.
    Hortobagyi, G. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 42S - 42S
  • [23] Capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC): High efficacy regardless of prior therapy
    Mauriac, L.
    Trainaud, A.
    Floquet, A.
    Donamaria, C.
    Durand, M.
    Brouste, V.
    Debled, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Ixabepilone/epiribicin combination as therapy for metastatic breast cancer - a phase Ib study
    Roche, H.
    Zambetti, M.
    Dalenc, F.
    De Benedictis, E.
    Gladieff, L.
    Mudenda, B.
    Messina, M.
    Lainas, I.
    Gianni, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 267 - 268
  • [25] Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer
    Corey-Lisle, Patricia K.
    Peck, Ronald
    Mukhopadhyay, Pralay
    Orsini, Lucinda
    Safikhani, Shima
    Bell, Jill A.
    Hortobagyi, Gabriel
    Roche, Henri
    Conte, Pierfranco
    Revicki, Dennis A.
    CANCER, 2012, 118 (02) : 461 - 468
  • [26] Frontline docetaxel (T) capecitabine M combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study.
    Chun, JH
    Lee, HG
    Lee, ES
    Kim, E
    Oh, JH
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 71S - 71S
  • [27] Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer
    Lv, Huimin
    Yan, Min
    Zhang, Mengwei
    Niu, Limin
    Zeng, Huiai
    Cui, Shude
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (06) : 692 - 697
  • [28] Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC).
    Beslija, S.
    Obralic, N.
    Basic, H.
    Tatarevic, A.
    Naila, M.
    Banjin, M.
    Cardzic, A.
    Sosevic, A.
    Pasic, A.
    Ceric, T.
    Salkic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 20S - 20S
  • [29] Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
    Feng, Mengya
    Bi, Pingping
    Kang, Yihua
    Yang, Dechun
    Ren, Shengnan
    Lu, Xianping
    Xie, Guojian
    Lei, Hai
    Mo, Dan
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [30] Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer
    Ohno, Shinji
    Mitsuyama, Shoshu
    Tamura, Kazuo
    Nishimura, Reiki
    Tanaka, Maki
    Hamada, Yuzo
    Kuroki, Shoji
    ANTICANCER RESEARCH, 2007, 27 (02) : 1009 - 1013
12345